Trial Profile
A Phase 2, Single-masked, Randomized, Crossover Study Of The 24-hour Intraocular Pressure Lowering And Systemic Exposure of Pf-04217329 Alone And In Combination With Latanoprost
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 May 2021
Price :
$35
*
At a glance
- Drugs Taprenepag (Primary) ; Latanoprost
- Indications Ocular hypertension; Open-angle glaucoma
- Focus Pharmacokinetics; Therapeutic Use
- Sponsors Pfizer
- 12 May 2014 New trial record